Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade SAN DIEGO and PARSIPPANY, N.J., Jan. 25, 2023...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news